Results 71 to 80 of about 218,137 (296)

EDNRB‐dependent endothelin signaling reduces proliferation and promotes proneural‐to‐mesenchymal transition in gliomas

Molecular Oncology, EarlyView.
Glioma cells mainly express the endothelin receptor EDNRB, while EDNRA is restricted to a perivascular tumor subpopulation. Endothelin signaling reduces glioma cell proliferation while promoting migration and a proneural‐to‐mesenchymal transition associated with poor prognosis. This pathway activates Ca2+, K+, ERK, and STAT3 signalings and is regulated
Donovan Pineau, Leonor Garcia, Hugo Arnold, Antonija Hanžek, Maialen Arrieta, Laurent R Gauthier, Christine Granotier‐Beckers, François D Boussin, Amaury Herbet, Marie Hautière, Valentin Asei‐Ceschino, Clémentin Jacques, Laura Brard, Thomas Harnois, Valérie Coronas, Bruno Constantin, Aurélien Chatelier, Jean Chemin, Serge Urbach, Martial Seveno, Szimonetta Hideg, Chantal Ripoll, Kasandra Aguilar‐Cázarez, Min Zheng, Guo‐Hao Huang, Sheng‐Qing Lv, Lei Zhang, Philippe Rondard, Laurent Prezeau, Jean‐Philippe Pin, Hugues Duffau, Luc Bauchet, Valérie Rigau, Franck Denat, Charles Truillet, Didier Boquet, Jean‐Philippe Hugnot   +36 more
wiley   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. [PDF]

, 2019
Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune responses ...
Arrillaga-Romany, Isabel C, Butowski, Nicholas A, Clarke, Jennifer L, Cloughesy, Timothy F, Cohen, Adam L, Colman, Howard, Davidson, Tom B, de Groot, John F, Du, Lin, Ellingson, Benjamin M, Gaffey, Sarah C, Hugo, Willy, Kaley, Thomas J, Kawaguchi, Eric S, Lee, Alexander H, Lee, Eudocia Q, Li, Gang, Liau, Linda M, Mellinghoff, Ingo K, Mochizuki, Aaron Y, Nghiemphu, Phioanh L, O'Brien, Barbara J, Orpilla, Joey R, Prins, Robert M, Reardon, David A, Rytlewski, Julie A, Sanders, Catherine M, Wang, Anthony C, Wen, Patrick Y, Yong, William H   +29 more
core  

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma [PDF]

Journal of Clinical Oncology, 2016
PurposeExpression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti–programmed death 1 (PD-1). This study explored the relationship between anti–PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 ...
Daud, Adil I, Wolchok, Jedd D, Robert, Caroline, Hwu, Wen-Jen, Weber, Jeffrey S, Ribas, Antoni, Hodi, F Stephen, Joshua, Anthony M, Kefford, Richard, Hersey, Peter, Joseph, Richard, Gangadhar, Tara C, Dronca, Roxana, Patnaik, Amita, Zarour, Hassane, Roach, Charlotte, Toland, Grant, Lunceford, Jared K, Li, Xiaoyun Nicole, Emancipator, Kenneth, Dolled-Filhart, Marisa, Kang, S Peter, Ebbinghaus, Scot, Hamid, Omid   +23 more
openaire   +4 more sources

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma [PDF]

, 2017
Background Immune checkpoint inhibitors targeting programmed cell death 1 (PD1) or its ligand (PD-L1) showed activity in several cancer types. Methods We performed immunohistochemistry for CD3, CD8, CD20, HLA-DR, phosphatase and tensin homolog (PTEN), PD-
Berghoff, Anna Sophie, Brandstetter, Anita, Dieckmann, Karin, Filipits, Martin, Hainfellner, Johannes A., Hegi, Monika E., Kiesel, Barbara, Kurscheid, Sebastian, Marosi, Christine, Preusser, Matthias, Rajky, Orsolya, Ricken, Gerda, Weller, Michael, Wick, Wolfgang, Widhalm, Georg, Wöhrer, Adelheid, Zielinski, Christoph C.   +16 more
core  

The convergence of radiation and immunogenic cell death signaling pathways. [PDF]

, 2012
Ionizing radiation (IR) triggers programmed cell death in tumor cells through a variety of highly regulated processes. Radiation-induced tumor cell death has been studied extensively in vitro and is widely attributed to multiple distinct mechanisms ...
Barcellos-Hoff, Mary H, Demaria, Sandra, Formenti, Silvia C, Golden, Encouse B, Pellicciotta, Ilenia   +4 more
core   +2 more sources

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo

Journal of the Egyptian Women’s Dermatologic Society
Background Programmed cell death 1 (PD-1) is a cell surface protein that serves as an immune checkpoint in conjunction with its two ligands, PD-L1 and PD-L2.
Hanan R. Nada, Ahmed Mourad, Laila A. Rashed, Ghada M. El-Hanafy, Nermeen M.A. Abdallah, Mohamed M. Abdelhady   +5 more
doaj   +1 more source

Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]

, 2020
Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth, Koyfman, Alex, Long, Brit Jeffrey   +2 more
core